TY - JOUR
T1 - Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons
AU - Akiyama, Tetsuya
AU - Suzuki, Naoki
AU - Ishikawa, Mitsuru
AU - Fujimori, Koki
AU - Sone, Takefumi
AU - Kawada, Jiro
AU - Funayama, Ryo
AU - Fujishima, Fumiyoshi
AU - Mitsuzawa, Shio
AU - Ikeda, Kensuke
AU - Ono, Hiroya
AU - Shijo, Tomomi
AU - Osana, Shion
AU - Shirota, Matsuyuki
AU - Nakagawa, Tadashi
AU - Kitajima, Yasuo
AU - Nishiyama, Ayumi
AU - Izumi, Rumiko
AU - Morimoto, Satoru
AU - Okada, Yohei
AU - Kamei, Takayuki
AU - Nishida, Mayumi
AU - Nogami, Masahiro
AU - Kaneda, Shohei
AU - Ikeuchi, Yoshiho
AU - Mitsuhashi, Hiroaki
AU - Nakayama, Keiko
AU - Fujii, Teruo
AU - Warita, Hitoshi
AU - Okano, Hideyuki
AU - Aoki, Masashi
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/7
Y1 - 2019/7
N2 - Background: The characteristic structure of motor neurons (MNs), particularly of the long axons, becomes damaged in the early stages of amyotrophic lateral sclerosis (ALS). However, the molecular pathophysiology of axonal degeneration remains to be fully elucidated. Method: Two sets of isogenic human-induced pluripotent stem cell (hiPSCs)-derived MNs possessing the single amino acid difference (p.H517D) in the fused in sarcoma (FUS) were constructed. By combining MN reporter lentivirus, MN specific phenotype was analyzed. Moreover, RNA profiling of isolated axons were conducted by applying the microfluidic devices that enable axon bundles to be produced for omics analysis. The relationship between the target gene, which was identified as a pathological candidate in ALS with RNA-sequencing, and the MN phenotype was confirmed by intervention with si-RNA or overexpression to hiPSCs-derived MNs and even in vivo. The commonality was further confirmed with other ALS-causative mutant hiPSCs-derived MNs and human pathology. Findings: We identified aberrant increasing of axon branchings in FUS-mutant hiPSCs-derived MN axons compared with isogenic controls as a novel phenotype. We identified increased level of Fos-B mRNA, the binding target of FUS, in FUS-mutant MNs. While Fos-B reduction using si-RNA or an inhibitor ameliorated the observed aberrant axon branching, Fos-B overexpression resulted in aberrant axon branching even in vivo. The commonality of those phenotypes was further confirmed with other ALS causative mutation than FUS. Interpretation: Analyzing the axonal fraction of hiPSC-derived MNs using microfluidic devices revealed that Fos-B is a key regulator of FUS-mutant axon branching. Fund: Japan Agency for Medical Research and development; Japanese Ministry of Education, Culture, Sports, Science and Technology Clinical Research, Innovation and Education Center, Tohoku University Hospital; Japan Intractable Diseases (Nanbyo) Research Foundation; the Kanae Foundation for the Promotion of Medical Science; and “Inochi-no-Iro” ALS research grant.
AB - Background: The characteristic structure of motor neurons (MNs), particularly of the long axons, becomes damaged in the early stages of amyotrophic lateral sclerosis (ALS). However, the molecular pathophysiology of axonal degeneration remains to be fully elucidated. Method: Two sets of isogenic human-induced pluripotent stem cell (hiPSCs)-derived MNs possessing the single amino acid difference (p.H517D) in the fused in sarcoma (FUS) were constructed. By combining MN reporter lentivirus, MN specific phenotype was analyzed. Moreover, RNA profiling of isolated axons were conducted by applying the microfluidic devices that enable axon bundles to be produced for omics analysis. The relationship between the target gene, which was identified as a pathological candidate in ALS with RNA-sequencing, and the MN phenotype was confirmed by intervention with si-RNA or overexpression to hiPSCs-derived MNs and even in vivo. The commonality was further confirmed with other ALS-causative mutant hiPSCs-derived MNs and human pathology. Findings: We identified aberrant increasing of axon branchings in FUS-mutant hiPSCs-derived MN axons compared with isogenic controls as a novel phenotype. We identified increased level of Fos-B mRNA, the binding target of FUS, in FUS-mutant MNs. While Fos-B reduction using si-RNA or an inhibitor ameliorated the observed aberrant axon branching, Fos-B overexpression resulted in aberrant axon branching even in vivo. The commonality of those phenotypes was further confirmed with other ALS causative mutation than FUS. Interpretation: Analyzing the axonal fraction of hiPSC-derived MNs using microfluidic devices revealed that Fos-B is a key regulator of FUS-mutant axon branching. Fund: Japan Agency for Medical Research and development; Japanese Ministry of Education, Culture, Sports, Science and Technology Clinical Research, Innovation and Education Center, Tohoku University Hospital; Japan Intractable Diseases (Nanbyo) Research Foundation; the Kanae Foundation for the Promotion of Medical Science; and “Inochi-no-Iro” ALS research grant.
KW - Amyotrophic lateral sclerosis (ALS)
KW - Axon branching
KW - Fos-B
KW - Fused in sarcoma (FUS)
KW - Human-induced pluripotent stem cell (hiPSC)-derived motor neuron
KW - Nerve organoid
UR - http://www.scopus.com/inward/record.url?scp=85068076632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068076632&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2019.06.013
DO - 10.1016/j.ebiom.2019.06.013
M3 - Article
C2 - 31262712
AN - SCOPUS:85068076632
SN - 2352-3964
VL - 45
SP - 362
EP - 378
JO - EBioMedicine
JF - EBioMedicine
ER -